BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. KLN-1010, a novel, in vivo CAR-T cell therapy candidate for the treatment of multiple myeloma, which leverages the company’s in vivo Gene Placement System (iGPS®) technology, demonstrated that it is safe and effective in preclinical animal models. “These data reinforce the best-in-class potential of our in vivo CAR-T cell therapies,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. “By eliminating the need for ex vivo manufacturing and toxic lymphodepleting chemotherapy, we believe our iGPS technology will remove barriers that currently prevent patients from accessing transformative genetic medicines. We are excited by the preclinical profile of KLN-1010, and are looking forward to advancing this program towards the clinic in the near future.”. Diverse T cell lineages, including memory and effector CD4 and CD8 T cells were modified in vivo by KLN-1010 to express a fully human anti-BCMA CAR, without detectable transduction of multiple myeloma tumor cells

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors. “Kristen and Mathai are joining during an exciting time as we continue to shepherd our lead in vivo anti-BCMA CAR program into the clinic and expand our pipeline into additional therapeutic areas to reach even more patients in need,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. “Their insight and expertise in developing numerous impactful medicines will be invaluable as we unlock the full potential of our potent and tissue-specific iGPS gene delivery platform, starting in multiple myeloma.”. Dr. Hege stated, “The first wave of CAR-T cell therapies have been unquestionable breakthroughs in treating blood cancer. However, challenges posed by the complexity and time requirements for ex vivo manufacturing of autologous CAR-T cell products may limit patient access to these breakthrough therapies

Xyphos, a wholly owned subsidiary of Astellas Pharma, and Kelonia announced a nearly $800 million research collaboration and license agreement to develop innovative universal, off-the-shelf in vivo CAR T cell therapies.